Next Article in Journal
Psychological Interventions for Children with Autism during the COVID-19 Pandemic through a Remote Behavioral Skills Training Program
Previous Article in Journal
The Impact of SARS-CoV-2 Primary Vaccination in a Cohort of Patients Hospitalized for Acute COVID-19 during Delta Variant Predominance
Previous Article in Special Issue
Immune Response of Adult Sickle Cell Disease Patients after COVID-19 Vaccination: The Experience of a Greek Center
Brief Report

Thromboprophylaxis Reduced Venous Thromboembolism in Sickle Cell Patients with Central Venous Access Devices: A Retrospective Cohort Study

1
Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G 2C4, Canada
2
Sickle Cell Referral Center, Department of Internal Medicine, Henri Mondor University Hospital, UPEC, APHP, 94000 Créteil, France
3
Laboratoire D’Excellence, GRex, Institut Mondor, INSERM U955 Equipe 2, 94000 Créteil, France
*
Author to whom correspondence should be addressed.
Academic Editor: Eleni Gavriilaki
J. Clin. Med. 2022, 11(5), 1193; https://doi.org/10.3390/jcm11051193
Received: 25 January 2022 / Revised: 14 February 2022 / Accepted: 18 February 2022 / Published: 23 February 2022
(This article belongs to the Special Issue Sickle Cell Disease: Current Understanding and Future Options)
Sickle cell disease (SCD) induces a chronic prothrombotic state. Central venous access devices (CVADs) are commonly used for chronic transfusions and iron chelation in this population. CVADs are an additional venous thromboembolism (VTE) risk factor. The role of thromboprophylaxis in this setting is uncertain. The objectives are: (1) to determine whether thromboprophylaxis reduces VTE risk in SCD patients with CVAD and (2) to explore characteristics associated with VTE risk. We identified adults with SCD and CVAD intended for chronic use (≥3 months) at two comprehensive SCD centers. Thromboprophylaxis presence; type; intensity; and patient-, catheter-, and treatment-related VTE risk factors were recorded. Among 949 patients, 49 had a CVAD (25 without and 24 with VTE prophylaxis). Thromboprophylaxis type and intensity varied widely. Patients without thromboprophylaxis had higher VTE rates (rate ratio (RR) = 4.0 (95% confidence interval: 1.2–12.6), p = 0.02). Hydroxyurea was associated with lower VTE rates (RR = 20.5 (6.4–65.3), p < 0.001). PICC lines and Vortex and Xcela Power implantable devices were associated with higher rates compared with Port-a-Cath (RR = 5.8 (1.3–25.9), p = 0.02, and RR = 58.2 (15.0–225.0), p < 0.001, respectively). Thromboprophylaxis, hydroxyurea, and CVAD subtype were independently associated with VTE. The potentially protective role of thromboprophylaxis and hydroxyurea for VTE prevention in patients with SCD and CVAD merits further exploration. View Full-Text
Keywords: anemia; sickle cell; central venous catheters; upper extremity deep vein thrombosis; vascular access devices; venous thromboembolism anemia; sickle cell; central venous catheters; upper extremity deep vein thrombosis; vascular access devices; venous thromboembolism
Show Figures

Figure 1

MDPI and ACS Style

Forté, S.; De Luna, G.; Abdulrehman, J.; Fadiga, N.; Pestrin, O.; Pham Hung d’Alexandry d’Orengiani, A.-L.; Aneke, J.C.; Guillet, H.; Budhram, D.; Habibi, A.; Ward, R.; Bartolucci, P.; Kuo, K.H.M. Thromboprophylaxis Reduced Venous Thromboembolism in Sickle Cell Patients with Central Venous Access Devices: A Retrospective Cohort Study. J. Clin. Med. 2022, 11, 1193. https://doi.org/10.3390/jcm11051193

AMA Style

Forté S, De Luna G, Abdulrehman J, Fadiga N, Pestrin O, Pham Hung d’Alexandry d’Orengiani A-L, Aneke JC, Guillet H, Budhram D, Habibi A, Ward R, Bartolucci P, Kuo KHM. Thromboprophylaxis Reduced Venous Thromboembolism in Sickle Cell Patients with Central Venous Access Devices: A Retrospective Cohort Study. Journal of Clinical Medicine. 2022; 11(5):1193. https://doi.org/10.3390/jcm11051193

Chicago/Turabian Style

Forté, Stéphanie, Gonzalo De Luna, Jameel Abdulrehman, Nafanta Fadiga, Olivia Pestrin, Anne-Laure Pham Hung d’Alexandry d’Orengiani, John C. Aneke, Henri Guillet, Dalton Budhram, Anoosha Habibi, Richard Ward, Pablo Bartolucci, and Kevin H.M. Kuo. 2022. "Thromboprophylaxis Reduced Venous Thromboembolism in Sickle Cell Patients with Central Venous Access Devices: A Retrospective Cohort Study" Journal of Clinical Medicine 11, no. 5: 1193. https://doi.org/10.3390/jcm11051193

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop